Physician profile
Patrick Safo
NPI 1104088202
$52,833.89
in general payments reported to CMS, 2019-2025
25 companies · $903 in 2025
The $903 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $29K · 2020: $6,521 · 2021: $14K · 2022: $1,097 · 2023: $668 · 2024: $1,171 · 2025: $903.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,450 · Education: $292.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,449.75 |
| Education | $292.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $28,580.19 | 2019 | |
| Janssen Scientific Affairs, LLC | $11,521.87 | 2021-2022 | |
| Amgen INC. | $7,921.87 | 2020-2025 | Otezla, Otezla |
| Janssen Biotech, INC. | $1,977.76 | 2019-2025 | Tremfya, Simponi Aria, Simponi |
| Abbvie INC. | $581.23 | 2019-2025 | Skyrizi, Rinvoq |
| Genzyme Corporation | $545.51 | 2022-2025 | |
| Pfizer INC. | $317.96 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $236.59 | 2022-2025 | |
| Regeneron Healthcare Solutions, INC. | $230.51 | 2022-2025 | Libtayo |
| Lilly USA, LLC | $145.73 | 2021-2025 | Taltz, Olumiant, Ebglyss |
| Incyte Corporation | $140.89 | 2022-2023 | Opzelura |
| Smith+Nephew, INC. | $114.47 | 2021-2024 | Grafix Pl, Grafix |
| Leo Pharma INC. | $104.84 | 2023-2025 | Adbry, Anzupgo |
| Sun Pharmaceutical Industries INC. | $91.69 | 2022-2025 | Odomzo, Blu-U |
| Galderma Laboratories, L.P. | $66.56 | 2024-2025 | Nemluvio |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $65.27 | 2022-2024 | Sotyktu |
| Organogenesis INC. | $34.42 | 2023 | Puraply |
| Kyowa Kirin, INC. | $25.48 | 2024 | Poteligeo |
| Ucb, INC. | $23.75 | 2025 | Bimzelx |
| Organon LLC | $19.51 | 2025 | Vtama |
| Biowound Solutions, INC. | $19.28 | 2025 | Bio-Connekt |
| Dermavant Sciences, INC. | $19.13 | 2023 | Vtama |
| Arcutis Biotherapeutics, INC. | $17.60 | 2024 | Zoryve |
| Oxford Immunotec USA INC | $17.02 | 2022 | |
| Kerecis Limited | $14.76 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patrick Safo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.